Logo image of CYRX

CRYOPORT INC (CYRX) Stock Fundamental Analysis

NASDAQ:CYRX - Nasdaq - US2290503075 - Common Stock - Currency: USD

6.67  -0.23 (-3.33%)

After market: 6.67 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CYRX. CYRX was compared to 55 industry peers in the Life Sciences Tools & Services industry. CYRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CYRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CYRX had negative earnings in the past year.
In the past year CYRX has reported a negative cash flow from operations.
CYRX had negative earnings in each of the past 5 years.
CYRX had negative operating cash flow in 4 of the past 5 years.
CYRX Yearly Net Income VS EBIT VS OCF VS FCFCYRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

CYRX's Return On Assets of -16.55% is in line compared to the rest of the industry. CYRX outperforms 47.27% of its industry peers.
The Return On Equity of CYRX (-29.05%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -16.55%
ROE -29.05%
ROIC N/A
ROA(3y)-11.01%
ROA(5y)-14.42%
ROE(3y)-20.23%
ROE(5y)-24.9%
ROIC(3y)N/A
ROIC(5y)N/A
CYRX Yearly ROA, ROE, ROICCYRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

CYRX has a Gross Margin (44.92%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of CYRX has declined.
The Profit Margin and Operating Margin are not available for CYRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-3.2%
CYRX Yearly Profit, Operating, Gross MarginsCYRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

CYRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CYRX has more shares outstanding
CYRX has more shares outstanding than it did 5 years ago.
CYRX has a better debt/assets ratio than last year.
CYRX Yearly Shares OutstandingCYRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CYRX Yearly Total Debt VS Total AssetsCYRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.25, we must say that CYRX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CYRX (-0.25) is worse than 74.55% of its industry peers.
CYRX has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
CYRX has a Debt to Equity ratio (0.47) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Altman-Z -0.25
ROIC/WACCN/A
WACC7.87%
CYRX Yearly LT Debt VS Equity VS FCFCYRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 5.56 indicates that CYRX has no problem at all paying its short term obligations.
CYRX has a better Current ratio (5.56) than 74.55% of its industry peers.
A Quick Ratio of 5.24 indicates that CYRX has no problem at all paying its short term obligations.
CYRX has a better Quick ratio (5.24) than 81.82% of its industry peers.
Industry RankSector Rank
Current Ratio 5.56
Quick Ratio 5.24
CYRX Yearly Current Assets VS Current LiabilitesCYRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

CYRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.11%, which is quite impressive.
Looking at the last year, CYRX shows a decrease in Revenue. The Revenue has decreased by -4.53% in the last year.
The Revenue has been growing by 46.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)59.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.88%
Revenue 1Y (TTM)-4.53%
Revenue growth 3Y0.86%
Revenue growth 5Y46.45%
Sales Q2Q%-24.82%

3.2 Future

The Earnings Per Share is expected to grow by 10.04% on average over the next years. This is quite good.
Based on estimates for the next years, CYRX will show a small growth in Revenue. The Revenue will grow by 0.42% on average per year.
EPS Next Y8.44%
EPS Next 2Y11.77%
EPS Next 3Y10.02%
EPS Next 5Y10.04%
Revenue Next Year-25.52%
Revenue Next 2Y-9.65%
Revenue Next 3Y-3.81%
Revenue Next 5Y0.42%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CYRX Yearly Revenue VS EstimatesCYRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
CYRX Yearly EPS VS EstimatesCYRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CYRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CYRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYRX Price Earnings VS Forward Price EarningsCYRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYRX Per share dataCYRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.77%
EPS Next 3Y10.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRYOPORT INC

NASDAQ:CYRX (6/13/2025, 8:00:01 PM)

After market: 6.67 0 (0%)

6.67

-0.23 (-3.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners98.32%
Inst Owner Change-2.41%
Ins Owners3.31%
Ins Owner Change13.07%
Market Cap334.43M
Analysts78.75
Price Target11.16 (67.32%)
Short Float %5.66%
Short Ratio5.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.32%
Min EPS beat(2)-40.53%
Max EPS beat(2)13.89%
EPS beat(4)3
Avg EPS beat(4)23.57%
Min EPS beat(4)-40.53%
Max EPS beat(4)93.29%
EPS beat(8)4
Avg EPS beat(8)-42.43%
EPS beat(12)5
Avg EPS beat(12)-33.13%
EPS beat(16)6
Avg EPS beat(16)-30.33%
Revenue beat(2)0
Avg Revenue beat(2)-2.8%
Min Revenue beat(2)-5.29%
Max Revenue beat(2)-0.31%
Revenue beat(4)0
Avg Revenue beat(4)-3%
Min Revenue beat(4)-5.29%
Max Revenue beat(4)-0.31%
Revenue beat(8)0
Avg Revenue beat(8)-3.87%
Revenue beat(12)1
Avg Revenue beat(12)-4.07%
Revenue beat(16)3
Avg Revenue beat(16)-2.92%
PT rev (1m)-1.99%
PT rev (3m)-3.15%
EPS NQ rev (1m)10.8%
EPS NQ rev (3m)9.52%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.11%
Revenue NQ rev (1m)-5.58%
Revenue NQ rev (3m)-31.76%
Revenue NY rev (1m)-5.39%
Revenue NY rev (3m)-30.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.56
P/FCF N/A
P/OCF N/A
P/B 0.84
P/tB 1.44
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS4.28
BVpS7.95
TBVpS4.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.55%
ROE -29.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.92%
FCFM N/A
ROA(3y)-11.01%
ROA(5y)-14.42%
ROE(3y)-20.23%
ROE(5y)-24.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-3.2%
F-Score4
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.52%
Cap/Sales 9.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.56
Quick Ratio 5.24
Altman-Z -0.25
F-Score4
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)112.93%
Cap/Depr(5y)112.05%
Cap/Sales(3y)12.92%
Cap/Sales(5y)12.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.88%
EPS Next Y8.44%
EPS Next 2Y11.77%
EPS Next 3Y10.02%
EPS Next 5Y10.04%
Revenue 1Y (TTM)-4.53%
Revenue growth 3Y0.86%
Revenue growth 5Y46.45%
Sales Q2Q%-24.82%
Revenue Next Year-25.52%
Revenue Next 2Y-9.65%
Revenue Next 3Y-3.81%
Revenue Next 5Y0.42%
EBIT growth 1Y28.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.96%
EBIT Next 3Y27.07%
EBIT Next 5Y17.56%
FCF growth 1Y-29.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4450%
OCF growth 3YN/A
OCF growth 5YN/A